Skip Navigation


Annals of Oncology Advance Access originally published online on January 11, 2007
Annals of Oncology 2007 18(4):782-788; doi:10.1093/annonc/mdl469
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/4/782    most recent
mdl469v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Thomas, A.
Right arrow Articles by Wiedenmann, B
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thomas, A.
Right arrow Articles by Wiedenmann, B
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

phase I and pharmacokinetics

A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer

AL Thomas1,*, T Trarbach2, C Bartel3, D Laurent4, A Henry5, M Poethig4, J Wang5, E Masson5, W Steward1, U Vanhoefer2 and B Wiedenmann3

1 University of Leicester, Leicester, UK
2 University of Duisburg-Essen Medical School, West German Cancer Center, Essen
3 Charite University Hospital CVK, Berlin
4 Schering AG, Berlin, Germany
5 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

* Correspondence to: Dr A. L. Thomas, Department of Oncology, Leicester Royal Infirmary, Leicester LE1 5WW, UK. Tel: +44-116-2587602; Fax: +44-116-2587599; E-mail: at107{at}le.ac.uk

Background: This open-label, phase IB study was undertaken to determine the safety/toxicity profile and recommended dose of oral once-daily PTK787/ZK 222584 (PTK/ZK) combined with oxaliplatin/5-fluorouracil (5-FU)/leucovorin (FOLFOX4) chemotherapy in patients with advanced colorectal cancer. Secondary objectives were to assess full pharmacokinetics and gather preliminary evidence of antitumor activity.

Patients and methods: Thirty-five patients received escalating doses of PTK/ZK (range 500–2000 mg daily) continuously. Concurrent FOLFOX4 chemotherapy was administered on days 1 and 2 and repeated every 14 days. Dose escalation of PTK/ZK was continued until maximum tolerated dose (MTD) was established and additional patients were then enrolled at MTD dosage.

Results: Mean treatment duration of PTK/ZK was 9.5 months. The MTD was 1250 mg daily with dizziness being the most frequent dose-limiting toxicity (DLT). Hypertension (23%, grade 3) and neutropenia (37%, grades 3 + 4) were the most frequent grade 3 or 4 adverse events. Pharmacokinetic analyses found no evidence for interactions between PTK/ZK and the combination of 5-FU, leucovorin, and oxaliplatin during concomitant use. Median progression-free survival was 11.4 months.

Conclusion: The MTD of PTK/ZK in combination with FOLFOX4 in this patient population is 1250 mg daily. The combination is feasible and safe and is not associated with significant pharmacokinetic interactions.

Key words: colorectal cancer, FOLFOX4 chemotherapy, phase I, PTK/ZK

Received for publication August 24, 2006. Revision received November 15, 2006. Accepted for publication November 16, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
JCOHome page
M. H.G. Langenberg, C. M.L. van Herpen, J. De Bono, J. H.M. Schellens, C. Unger, K. Hoekman, H. E. Blum, W. Fiedler, J. Drevs, F. Le Maulf, et al.
Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors
J. Clin. Oncol., December 20, 2009; 27(36): 6152 - 6159.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
J. Iwasaki and S.-i. Nihira
Anti-angiogenic Therapy Against Gastrointestinal Tract Cancers
Jpn. J. Clin. Oncol., September 1, 2009; 39(9): 543 - 551.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
C.-H. Kohne and H.-J. Lenz
Chemotherapy with Targeted Agents for the Treatment of Metastatic Colorectal Cancer
Oncologist, May 1, 2009; 14(5): 478 - 488.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T. Schomber, A. Zumsteg, K. Strittmatter, I. Crnic, H. Antoniadis, A. Littlewood-Evans, J. Wood, and G. Christofori
Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis
Mol. Cancer Ther., January 1, 2009; 8(1): 55 - 63.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.